Live news related to MEDINCELL stock (FR0004065605): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Medincell, a biopharmaceutical laboratory specializing in long-acting injectable treatments, announces its participation in the Leerink Global Healthc…
MedInCell shares fell 1.7% this Tuesday midday, trading at 24.26 euros on Euronext Paris. This decline occurs as the Montpellier-based biotech has jus…
Teva Pharmaceuticals and Medincell announce that the U.S. Food and Drug Administration has accepted the marketing authorization application for olanza…
MedInCell stock is up 2.6% this Monday morning at 24.50 euros, following a major regulatory announcement in the United States. The Montpellier-based c…
MedInCell's stock significantly advanced this Thursday, February 19, trading at 24.50 euros midday, marking an increase of 2.25% from the previous day…
MedInCell shares fell by 3.52% this Monday, February 16, to 24.14 euros, amid a three-month correction period. The price is now significantly below it…
ISS ESG has upgraded the non-financial rating of Medincell from C+ to B, according to a press release from the French biotech published on Tuesday, Fe…
Medincell's stock has seen a significant decline of 21.5% over the past week, closing at 22.56 euros on Friday. This drop occurs in a context of high …
Stifel ajuste sa cible sur Medincell ce jeudi 29 janvier 2026.
Medincell, through its partner Teva Pharmaceuticals, announces that the submission of a Marketing Authorization Application (MAA) for Olanzapine LAI i…
